Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Canopy Growth Corporation

The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock Valuations

Federal rescheduling efforts, coupled with improved corporate balance sheets, may finally unlock long-awaited profitability for cannabis-sector leaders.

MarketBeat

Canopy Growth Wraps Up Acreage Acquisition Expanding US Cannabis Portfolio, What Investors Need To Know

Canopy USA, LLC has wrapped up its acquisition of Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), Canopy Growth Corporation's (TSX: WEED) (NASDAQ: CGC) U.S.-domiciled holding company said on Monday. Canopy USA, created in 2022 to streamline the Canadian cannabis giant's entry into the US market, now owns 100% of…

Benzinga

Canopy Growth Names New CEO Who Will Succeed David Klein Amid US Expansion

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced on Tuesday its board of directors has named Luc Mongeau as the company's next chief executive officer, effective Jan. 6, 2025.Mongeau, a CPG veteran and current board member at the Canadian cannabis giant, succeeds CEO David Klein, who announced his plans to…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Canopy Growth's German Subsidiary Teams Up With Portugal's Gro-Vida To Expand Medical Cannabis Supply

Portugal-based medical marijuana grower Gro-Vida teamed up with Canopy Growth Germany GmbH, a subsidiary of cannabis giant Canopy Growth Corporation (NASDAQ:CGC). This agreement is a key step for Gro-Vida to position itself in Germany’s growing medical marijuana market while supporting Canopy Growth GmbH’s strategy of securing EU-based supply through an…

Benzinga

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com

Cannabis Check: Should You Consider Canopy Growth (CGC) and Tilray (TLRY) for Your 2024 Portfolio?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in Tilray Brands (TLRY) and Canopy Growth (CGC) this year? Keep reading….

StockNews.com

What Lies Ahead for SNDL Inc. (SNDL) and Canopy Growth (CGC)?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in SNDL Inc. (SNDL) and Canopy Growth (CGC) now? Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

What Should Pharma Investors Plan to Do With Canopy Growth (CGC) this Month?

Canadian cannabis producer Canopy Growth (CGC) reiterated ongoing concerns about its loss-making status. While the company is making significant efforts to return to profitability, is the stock worth buying now? Read on.

StockNews.com

Buy, Hold or Sell in July: Canopy Growth (CGC) and SNDL Inc. (SNDL)

Although the cannabis industry shows long-term growth potential, its near-term performance is hampered by intense regulations and limited financing. So, let's analyze whether you should Buy, Hold or Sell cannabis stocks SNDL (SNDL) and Canopy Growth (CGC).

StockNews.com

Is Canopy Growth (CGC) a Buy Under $2?

Canadian cannabis producer Canopy Growth (CGC) is making significant changes to its business model in an effort to turn profitable. However, given the regulatory challenges, will the company get success anytime soon? Let’s look at some of CGC’s metrics to understand if this penny stock is worth buying now.

StockNews.com

Sell the Farm on These 4 Cannabis Stocks

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

StockNews.com

3 Cannabis Stocks to Avoid Like the Plague in March 2023

The cannabis industry faced several challenges last year, including overproduction amid high inflation weighing on overall demand. With growing concerns over rising inflation and a looming recession, the industry is expected to remain under immense pressure this year. So, it could be wise to avoid fundamentally weak cannabis stocks Tilray…

StockNews.com

Marijuana Stocks: Buy or Sell These 3 in 2023?

Although several states have legalized marijuana, the industry faces a supply glut amid high inflation impacting overall demand. With Federal legalization unlikely this year, marijuana stocks could remain under pressure. Therefore, would it be wise to invest in marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB)…

StockNews.com

2 Marijuana Stocks to Sell Short, Liquidate or Avoid in 2023

The marijuana industry took a hit facing economic challenges. With no immediate hope of federal legalization, it may be a while until the U.S. government looks favorably toward pot stocks. Hence, fundamentally weak marijuana stocks Tilray Brands (TLRY) and Canopy Growth (CGC) might be best avoided this year. Continue reading….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Marijuana Stocks to Avoid Like the Plague

While marijuana legalization has been rising, the industry is witnessing increased regulations. Moreover, the sector’s revenues have been declining recently. Hence, marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), Sundial Growers (SNDL), and Aurora Cannabis (ACB) might be best avoided, given their weak fundamentals and negative profit margins. Keep reading.

Benzinga

Canopy Growth: Analyst Maintains Price Target Of $3.30, Stays Neutral After Q3 Results

Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED) recently reported its financial results for the third quarter that ended September 30, 2022 (&ldquo

Benzinga

Canopy Growth Q2 2023 Revenue Grows 7% Sequentially, Another Record Quarter For BioSteel

Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) Q2 FY2023 net revenue was CA$118 million ($87.8 million), a 10% decrease compared to Q2 FY2022.

StockNews.com

2 Marijuana Stocks That Are Nothing Short of Buzzkill

While the cannabis industry might be looking at a possible reversal of fortunes due to increased legalization for recreational and proven medicinal usage, fundamentally weak and beaten-down Marijuana stocks Tilray Brands (TLRY) and Canopy Growth (CGC) may be wealth destroyers. So, it could be wise for investors to avoid these…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Forget About SAFE Plus Or CLIMB Act As Cannabis Stock Catalysts, With Canopy's Potential Exception

Canopy Growth Corporation (NASDAQ: CGC)

Benzinga

This Is How It's Done: Why Is Canopy's US Consolidation Plan Blueprint For Other Canadian Cannabis LPs

Canadian cannabis giant Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) announced its intention to consolidate in the US via a new holding company dubbed Canopy

Benzinga

Canopy Growth Transfers Its TerrAscend Assets To Canopy USA Company

Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) and Canopy USA, LLC announced that each of the company and Canopy USA has filed an early warning report under National Instrument 62-103 - The early warning system and related take-over bid

Benzinga

Canopy's Shares Slightly Up On Plans To Conquer US Cannabis Market

Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED) is creating a new U.S.-domiciled holding company, Canopy USA, LLC. Canopy USA will hold the company's U.S.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

StockNews.com

3 Cannabis Stocks Going up in Flames to Avoid

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

Benzinga

Canopy Growth International Medical Cannabis Revenue Doubles In Q1, But What About Net Sales?

Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) released its financial results for the first quarter ended June 30, 2022, revealing net revenue of CA$110 million ($85.36 million) in Q1 FY2023 declined 19% versus Q1 FY2022.

1 2

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical – Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.